Sagimet Biosciences Inc. (NASDAQ: SGMT) has recently reported its financial results for the quarter ended March 31, 2025. The company remains in the clinical stage of developing its lead product, denifanstat, a novel fatty acid synthase (FASN) inhibitor targeting conditions such as metabolic dysf...